Skip to main content

AstraZeneca scraps £450m vaccine plant in Liverpool after Labour funding cut

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget, was dependent on a "mutual agreement" with the Treasury and third parties, it was said at the time.

It will no longer go ahead because Labour ministers have offered less funding than their predecessors, the pharmaceutical giant said. An AstraZeneca spokesperson told Sky News: "Following discussions with the current government, we are no longer pursuing our planned investment at Speke. "Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous government's proposal."

The money would have expanded an existing site in Speke and was hailed at the time as a "vote of confidence" in Liverpool and the UK's life science sector. The AstraZeneca spokesperson said that the Speke site "will continue to produce and supply our flu vaccine, for patients in the UK and around the world".

A government spokesperson said a "change in the make-up of the investment" proposed by AstraZeneca had "led to a reduced government grant offer being put forward". The spokesperson added: "All government grant funding has to demonstrate value for the taxpayer and unfortunately, despite extensive work from government officials, it has not been possible to achieve a solution.

"AstraZeneca remains closely engaged with the government's work to develop our new industrial strategy, and more broadly we continue to have a thriving life sciences sector, worth £108 billion to the economy and providing over 300,000 highly skilled jobs across the country." The decision is a blow to Rachel Reeves's renewed attempts to deliver economic growth. In a speech earlier this week which named AstraZeneca, the chancellor said life sciences would be key to boosting the economy. She announced plans to deliver an Oxford-Cambridge growth corridor, which she claimed would add up to £78bn to the public coffers.

Jeremy Hunt speaks to the media during a visit to the AstraZeneca Speke Factory.  Pic: HM Treasury

Image: Jeremy Hunt speaks to the media during a visit to the AstraZeneca Speke Factory. Pic: HM Treasury

Andrew Griffith, the shadow business secretary, said: "There's no vaccine for incompetence. In the same week they talked about growth, Labour seem to have fumbled a deal with AstraZeneca, one of the UK's largest companies and central to the critical life sciences sector." The new plant at Speke was intended to enhance the UK's pandemic preparedness. Reports that it was under threat emerged shortly after Labour won the general election, when ministers warned of the need to make cuts to infrastructure projects to fill a £22bn "black hole" in the public finances. The confirmation comes after former health secretary Matt Hancock said that the UK needed to improve its own vaccine manufacturing capability as a "critical" part of preparing for a future pandemic. Mr Hancock told the COVID Inquiry earlier in January that Britain's vaccine manufacturing capacity was "weak".

He added: "Having that manufacture and fill and finish onshore, physically within the UK, is critical in the way that it simply isn't in normal times."

https://worldnewsguru.us/?p=19461&network_id=

Comments

Popular posts from this blog

Dollar set for best week since November on US rates, economic outlook

By Rae Wee SINGAPORE () -The dollar was on track for its best weekly performance in over a month on Friday, underpinned by expectations of fewer Federal Reserve rate cuts this year and the view that the U.S. economy will continue to outperform the rest of its peers globally. The greenback began the new year on a strong note reaching a more than two-year high of 109.54 against a basket of currencies on Thursday as it extended a stellar rally from last year. Its charge higher has come on the back of a more hawkish Fed and a resilient U.S. economy. "Looks like dollar strength is here to stay for now in early 2025 given the U.S. exceptionalism story is here to stay, and it still comes with high U.S. yields," said Charu Chanana, chief investment strategist at Saxo. "Add to that the uncertainty from policies of the incoming (Donald) Trump administration, and you also get the safety aspect of the dollar looking attractive." Ahead of U.S. President-elect Trump'...

California's latest job-killing policy is more bad news for Golden Staters

California's latest job-killing policy is more bad news for Golden Staters California’s list of public policy failures was already long, but hiking its minimum wage to $20 an hour for fast-food workers may belong at the top. The predictable fallout in lost jobs and higher pr... Read more: https://worldnewsguru.us/business-news/californias-latest-jobkilling-policyis-more-bad-news-for-golden-staters Originally published on World News Guru

Trump push to use tariffs to pay for tax cuts faces opposition in Congress

By Jarrett Renshaw, David Morgan and David Lawder WASHINGTON () - U.S. President Donald Trump is pushing a plan to explicitly use revenue from higher tariffs on imported goods to help pay for extending trillions of dollars in tax cuts, an unprecedented shift likely to face opposition from many of his fellow Republicans in Congress. The U.S. collects less than $100 billion annually in trade penalties imposed on imported goods as a tool to protect and grow domestic industries. That money is rarely a topic in Washington's routine budget battles because it makes up so little of the federal government's revenue.  Trump has threatened across-the-board import tariffs, but has yet to impose any. The president and his allies say he wants to use them much like the personal and corporate taxes that account for the vast majority of U.S. revenues, notching up tariffs to help pay for government programs and cover promised tax cuts.  "Instead of taxing our citizens to enrich other...